- Resignation of Anthony Vernon and Appointment of Elisabeth Sandoval-Little - MENLO PARK, Calif. --(BUSINESS WIRE)--Apr. 5, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that

MENLO PARK, Calif., July 29, 2014 (GLOBE NEWSWIRE) -- Intersect ENT, Inc. (Nasdaq:XENT), a commercial drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions, today announced the closing of its initial public offering of 5,750,000 shares of

Approval Establishes New S Code for PROPEL to Facilitate Specific Coding & Payment MENLO PARK, Calif. --(BUSINESS WIRE)--Jan. 19, 2021-- Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that

MENLO PARK, Calif. --(BUSINESS WIRE)--Apr. 29, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, announced that the Company has changed the date of its previously scheduled first quarter 2021 financial

Christine Kowalski Joins as Chief Operations Officer; Susan Stimson Named Chief Strategy Officer MENLO PARK, Calif. --(BUSINESS WIRE)--Oct. 29, 2018-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today

Underwriters Exercise Option for 537,300 Shares of Common Stock, Increasing Total Aggregate Proceeds to Approximately $103.0 Million MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT , Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and